Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells $5,029,879.66 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 136,942 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66. Following the completion of the transaction, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $684,307,043.47. This trade represents a 0.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $36.84 on Friday. Roivant Sciences Ltd. has a 12 month low of $11.54 and a 12 month high of $37.97. The stock has a market capitalization of $26.61 billion, a PE ratio of -69.51 and a beta of 1.12. The business has a 50 day simple moving average of $34.48 and a 200-day simple moving average of $30.38.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $2.06 million. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Hedge Funds Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. SBI Securities Co. Ltd. raised its stake in Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in shares of Roivant Sciences in the 4th quarter valued at about $47,000. Finally, Bessemer Group Inc. increased its holdings in shares of Roivant Sciences by 21.8% in the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on ROIV. HC Wainwright boosted their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a “buy” rating in a report on Friday, August 7th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Guggenheim raised their target price on Roivant Sciences from $36.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.